News Sentiment

ARCT sentiment intelligence

Arcturus Therapeutics Holdings Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.97 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-4.3% over one week, +0.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -4.3% Price reacting lower
Trend fit Trend inactive 0.0% over four weeks
Fair value -62.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 40
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 11
TradingView 6
simplywall.st 6
TradingKey 5
Moomoo 3
Kavout | AI 2
Intellectia AI 1

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 22
Analyst action 6
Regulatory and legal 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
Kavout | AI Direct company coverage

Is Arcturus Therapeutics' ARCT-032 a Game Changer for Cystic Fibrosis

Arcturus Therapeutics (ARCT) is gaining attention for its inhaled mRNA therapeutic, ARCT-032, for cystic fibrosis, which is advancing to a pivotal Phase 2 study after promising early safety and mucus reduction data. The company has a robust mRNA platform, including self-amplifyin

Tone
Positive 71/100
Event
Market update
Published
12 Jul 2026 00:40
Source
Kavout | AI
Intellectia AI Direct company coverage

ARCT Should I Buy

This article analyzes whether Arcturus Therapeutics Holdings Inc (ARCT) is a good investment, concluding with a "Hold" recommendation for beginner long-term investors. While the stock benefits from supportive analyst coverage and a promising Thermo Fisher collaboration, its curre

Tone
Neutral 50/100
Event
Analyst action
Published
11 Jul 2026 01:41
Source
Intellectia AI
Quartr Direct company coverage

Arcturus Therapeutics (ARCT) Q1 2025 earnings summary

Arcturus Therapeutics (ARCT) reported its Q1 2025 earnings, highlighting a prioritized mRNA therapeutics pipeline focused on cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency programs. The company achieved EU and Japan approvals for KOSTAIVE®, its self-amplifyi

Tone
Positive 63/100
Event
Earnings
Published
09 Jul 2026 01:45
Source
Quartr
TradingView Direct company coverage

Price to sales forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT

This page displays the "Price to sales forward" metric for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT). It indicates that the market for ARCT was closed and no trades were recorded, providing various financial, news, and community tabs for further research.

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 22:40
Source
TradingView
Market source Direct company coverage

Thermo Fisher, Arcturus partner on Phase III ARCT-032 cystic fibrosis trial

Thermo Fisher Scientific has teamed up with Arcturus Therapeutics to advance ARCT-032, an investigational mRNA therapy for cystic fibrosis, into Phase III clinical trials. This collaboration will leverage Thermo Fisher's Accelerator Drug Development solutions for integrated manuf

Tone
Neutral 50/100
Event
Regulatory and legal
Published
03 Jul 2026 16:31
Source
Market source
Market source Direct company coverage

Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?

Arcturus Therapeutics (ARCT) stock jumped 5.7% after the company announced a strategic collaboration with Thermo Fisher Scientific for the phase III development and commercialization of its cystic fibrosis mRNA therapy, ARCT-032. While the stock saw a significant gain, its near-t

Tone
Positive 63/100
Event
Market update
Published
03 Jul 2026 10:41
Source
Market source
Market source Direct company coverage

Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis

Arcturus Therapeutics announced a strategic collaboration with Thermo Fisher Scientific to advance its investigational mRNA therapy, ARCT-032, for Cystic Fibrosis. This partnership will leverage Thermo Fisher's Accelerator™ Drug Development solutions for integrated manufacturing,

Tone
Positive 71/100
Event
Regulatory and legal
Published
03 Jul 2026 10:41
Source
Market source
GuruFocus Direct company coverage

ARCT Initiates Coverage by Freedom Broker -- Rating Set to Buy

Freedom Broker has initiated coverage on Arcturus Therapeutics (ARCT) with a "Buy" rating and a price target of $27.00. Despite this positive analyst outlook, GuruFocus assesses ARCT as 65.8% overvalued with a GF Value™ of $4.15 compared to its current market price of $6.88. The

Tone
Positive 59/100
Event
Analyst action
Published
02 Jul 2026 17:11
Source
GuruFocus
Finviz Direct company coverage

ARCT - Arcturus Therapeutics Holdings Inc Latest SEC Filings

This article provides key financial data and performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT), including its market capitalization, income, sales, per-share values, and various ratios. It also details the company's past and projected EPS and sales growth, inside

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 09:40
Source
Finviz
TradingView Direct company coverage

Price to earnings forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT

The article presents a financial data point for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) specifically focusing on its price-to-earnings forward ratio. The content appears to be a stub or a data visualization page from TradingView, indicating a value for this metric over

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 09:09
Source
TradingView
www.marketscreener.com Direct company coverage

Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2500 Growth Benchmark

Arcturus Therapeutics Holdings Inc. (NasdaqGM:ARCT) has been removed from the Russell 2500 Growth Benchmark, as announced on June 29, 2026. This news follows several other recent benchmark removals for the company, including from the Russell Small Cap Comp Growth, Russell 2000 Gr

Tone
Negative 36/100
Event
Market update
Published
29 Jun 2026 21:09
Source
www.marketscreener.com
TradingView Direct company coverage

Arcturus Therapeutics Holdings, Inc. Actuals & Estimates (NASDAQ:ARCT)

This article provides an overview of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), detailing its current stock price, historical performance, analyst forecasts, and financial data. It includes key financial metrics such as market capitalization, EBITDA, and recent earnings r

Tone
Negative 38/100
Event
Earnings
Published
26 Jun 2026 00:12
Source
TradingView
TradingView Direct company coverage

ARCT Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Arcturus Therapeutics Holdings Inc. (ARCT) stock for 2027, based on analyst opinions. It includes current stock performance, historical highs and lows, market capitalization, volatility, and details on past and upcoming earnin

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 18:39
Source
TradingView
Stock Traders Daily Direct company coverage

Discipline and Rules-Based Execution in ARCT Response

This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) using AI models, highlighting a near-term strong sentiment potentially challenging persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and offers three distinct trading str

Tone
Positive 67/100
Event
Market update
Published
21 Jun 2026 04:39
Source
Stock Traders Daily
TradingKey Direct company coverage

Arcturus Therapeutics Holdings Inc (ARCT) Risk Assessment: Volatility, Financial Risk & Investment Risk

Arcturus Therapeutics Holdings Inc (ARCT) currently holds a risk assessment score of 2.19, ranking 233 out of 389 in the Biotechnology & Medical Research industry. The company's beta value of 2.37 suggests higher volatility compared to the S&P 500. The assessment includes detaile

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 03:39
Source
TradingKey
Stock Titan Direct company coverage

ARCT SEC Filings - Arcturus Therape 10-K, 10-Q, 8-K Forms

This page provides comprehensive access to Arcturus Therapeutics (ARCT) SEC filings, including 10-K, 10-Q, and 8-K forms, along with insider trading information. It details a recent Q2 2025 earnings press release and a Schedule 13G/A filing from ARK Investment Management disclosi

Tone
Positive 59/100
Event
Earnings
Published
17 Jun 2026 03:40
Source
Stock Titan
TradingKey Direct company coverage

Arcturus Therapeutics Holdings Inc (ARCT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Arcturus Therapeutics Holdings Inc (ARCT), listing major shareholders and their proportional holdings, including Federated Hermes Global Investment Management Corp., ARK Investment Management LLC, and BlackRock Institutional Trust

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 03:40
Source
TradingKey
TradingKey Direct company coverage

Arcturus Therapeutics Holdings Inc

This article provides an overview of Arcturus Therapeutics Holdings Inc (ARCT), including its current stock price and market capitalization. It highlights that relevant data regarding the company's revenue breakdown by business segments and regional contribution have not been dis

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 03:40
Source
TradingKey
TradingKey Direct company coverage

Arcturus Therapeutics Holdings Inc (ARCT) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Arcturus Therapeutics Holdings Inc (ARCT), noting its current valuation score is 7.25, ranking 253 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -2.60, which is significantly bel

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 03:09
Source
TradingKey
TradingKey Direct company coverage

Arcturus Therapeutics Holdings Inc (ARCT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Arcturus Therapeutics Holdings Inc (ARCT) has an earnings forecast score of 8.00, ranking 163 out of 388 in its industry, with an average analyst price target of $21.50. Analysts predominantly recommend a "Buy" for ARCT, with 12 analysts contributing to the rating. The company's

Tone
Positive 72/100
Event
Earnings
Published
16 Jun 2026 12:39
Source
TradingKey
Stock Titan Direct company coverage

Arcturus Therapeutics (ARCT) director awarded 15,000 stock options at $7.30

Arcturus Therapeutics Holdings Inc. director John Markels was granted 15,000 stock options at an exercise price of $7.30 per share as part of his 2026 annual board compensation. These options, which expire on June 5, 2036, will vest monthly over one year from the grant date. Foll

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 04:10
Source
Stock Titan
Stock Titan Direct company coverage

Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 board grant

Arcturus Therapeutics Holdings Inc. director Moncef Slaoui was granted 15,000 stock options as part of his annual board compensation for 2026. These options, with an exercise price of $7.30 per share and an expiration date of June 5, 2036, will vest monthly over one year from the

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 02:39
Source
Stock Titan